INVENT COVID was a phase II study, which investigated the efficacy and safety of intravenous imatinib in acute respiratory distress syndrome induced by COVID-19 (Clinical Trials Identifier: NCT04794088). touchRESPIRATORY were delighted to speak with Dr. Leila Atmowihardjo (Amsterdam Medical Centers: Academic Medical Center, Amsterdam, The Netherlands) to discuss the aims, design, eligibility criteria and findings from INVENT COVID and what further research is planned to investigate imatinib in this indication.
The abstract ‘The efficacy and safety of intravenous imatinib in invasively ventilated patients with COVID-19 related acute respiratory distress syndrome (InventCOVID): a multicentre, randomised, double-blinded, placebo-controlled, phase II clinical study.’ was presented at ERS 2022, 4–6 September, 2022.
- What was the rationale for the use of imatinib in the treatment of COVID-19? (0:19)
- What were the aims, design and eligibility criteria of the INVENT COVID study? (1:34)
- What were the primary and secondary outcome measures of the study? (2:20)
- What were the findings of the study? (3:26)
- What questions remain unanswered regarding the use of imatinib in this indication, and what further research is planned? (4:08)
Disclosures: Leila Atmowihardjo has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In COVID-19
Findings from the COVA study of BIO101 in severe COVID-19: Girish B. Nair, ATS 2023
The COVA study (NCT04472728) was a double-blind, placebo-controlled phase 2 to 3 study that investigated BIO101 for the prevention of respiratory deterioration in hospitalized COVID-19. touchRESPIRATORY were delighted to speak with Dr. Girish B. Nair (Beaumont Health, Royal Oak, MI, USA) around the mechanism of action of BIO101, the design, inclusion criteria and findings from […]
Margaret Pisani, Research highlights in COVID-19 from 2022
Longitudinal studies into the long-term impact of COVID-19 are currently at the forefront of research, touchRESPIRATORY interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) about what to look out for in 2023 in this area. Disclosures: Margaret Pisani has nothing to disclose in relation to this video interview. Support: Interview and filming […]
Alan Kaplan: IPCRG COVID-19 and Respiratory Q&A – COVID-19 Controversies, Vaccination and Booster Doses
The IPCRG COVID-19 and Respiratory Q&A is providing evidence based COVID and respiratory advice to practising primary care clinicians. Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) answers questions from the Q&A on managing COVID-19, how to address the controversies surrounding the COVID-19 vaccines, and the immunity provided from COVID-19 vaccination and booster doses. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!